PD Imaging Biomarker Team at European Medicines Agency (EMA)

Experts of the Parkinson’s disease imaging biomarker team participated in a Scientific Advice meeting at the European Medicines Agency on October 7th 2015. The purpose of this meeting was to review the evidence provided to the Agency that supports the use of Molecular Imaging of the Dopamine Transporter as an enrichment biomarker in clinical trials targeting subjects at first signs and symptoms of PD. Team members from left: Steve Arneric, C-Path; Derek Hill, Ixico; Klaus Romero, C-Path; Patricia Cole, Takeda; Arthur Roach, Parkinson’s UK; Ken Marek, MNI; Diane Stephenson, C-Path; Dawn Matthews, ADm Diagnostics; Mark Gordon, Boerhinger Ingelheim.